> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Since Our Last Issue ...
- URL: https://www.fdaweb.com/since-our-last-issue-75/
- Published: 2022-05-15T12:00:00.000Z
- Updated: 2026-09-14T17:44:38.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5138299

**Ethicon** has acquired **Torax Medical**, which manufactures and markets the LINX Reflux Management System for treating gastro-esophageal reflux disease. The device is based on magnetic sphincter augmentation (MSA) technology and the procedure is currently available in the U.S. and European medical centers.

**BioLineRx Ltd.** has acquired **Agalimmune Ltd.**, a private UK-based company with an innovative, anti-cancer immunotherapy platform. Agalimmune’s lead compound is AGI-134, a synthetic alpha-Gal immunotherapy in development for solid tumors. AGI-134 works by harnessing the body’s pre-existing, anti-alpha-Gal antibodies to induce a systemic, specific anti-tumor response to the patient’s own tumor neo-antigens.

**Hologic** has completed the acquisition of **Cynosure**, Inc., a medical aesthetics systems and technologies firm, for $66 per share in cash. Hologic says that acquiring the company, combined with divesting its blood screening business, reshapes its business portfolio and makes it a faster growing company.